Osteoporosis treatment and fracture incidence: the ICARO longitudinal study
暂无分享,去创建一个
S. Adami | R. Gentilella | R. Nuti | G. Luisetto | O. B. O. A. Group | S. Minisola | G. Isaia | L. Sinigaglia | D. Agnusdei | S. Silvestri
[1] S. Adami,et al. Fracture Incidence and Characterization in Patients on Osteoporosis Treatment: The ICARO Study , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[2] T. Spector,et al. Perinatal outcome of singletons and twins after assisted conception: a systematic review of controlled studies , 2004, The New England journal of medicine.
[3] M. Hochberg,et al. Alendronate Reduces the Risk of Multiple Symptomatic Fractures: Results from the Fracture Intervention Trial , 2002, Journal of the American Geriatrics Society.
[4] R. Marcus,et al. Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. , 2002, Endocrine reviews.
[5] J. Reginster,et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. , 2001, The New England journal of medicine.
[6] D. Kiel,et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. , 2000, The American journal of medicine.
[7] H K Genant,et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. , 1999, JAMA.
[8] C C Glüer,et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. , 1999, JAMA.
[9] A. LaCroix,et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. , 1998, JAMA.
[10] S. Cummings,et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures , 1996, The Lancet.
[11] M. Hooper,et al. Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis , 2000, Osteoporosis International.
[12] Harry K. Genant,et al. Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene: Results From a 3-year Randomized Clinical Trial , 2000 .